Jill Ohar to Pulmonary Disease, Chronic Obstructive
This is a "connection" page, showing publications Jill Ohar has written about Pulmonary Disease, Chronic Obstructive.
Connection Strength
9.943
-
Ohar JA, Sharma S, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sanjar S. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies. COPD. 2019 04; 16(2):133-139.
Score: 0.583
-
Ohar JA, Bowling A, Goodin T, Price B, Ozol-Godfrey A, Sharma S, Sanjar S. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies. Int J Chron Obstruct Pulmon Dis. 2019; 14:461-470.
Score: 0.569
-
Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019; 14:27-37.
Score: 0.562
-
Ohar J, Putcha N, Bradshaw M. Asthma-Chronic Obstructive Pulmonary Disease Overlap: Diagnostic and Management Challenges. J Fam Pract. 2018 10; 67(10 Suppl):S46-S51.
Score: 0.554
-
Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal Inspiratory Flow Rates Are Associated with Chronic Obstructive Pulmonary Disease and All-Cause Readmissions. Ann Am Thorac Soc. 2017 Aug; 14(8):1305-1311.
Score: 0.511
-
Ohar JA. Medicare Bundled Payments for Care Improvement Initiative for Chronic Obstructive Pulmonary Disease Readmissions: A Negative Study That Has Positive Implications. Ann Am Thorac Soc. 2017 05; 14(5):617-618.
Score: 0.502
-
Ohar JA, Yawn BP, Ruppel GL, Donohue JF. A retrospective study of two populations to test a simple rule for spirometry. BMC Fam Pract. 2016 06 04; 17:65.
Score: 0.472
-
Cohen JS, Miles MC, Donohue JF, Ohar JA. Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis. 2016; 11:785-97.
Score: 0.467
-
Ohar JA. Risks May Not Be Reasons for COPD Readmissions. Ann Am Thorac Soc. 2015 Sep; 12(9):1259-60.
Score: 0.447
-
Davidson JF, Donohue JF, Ohar JA. Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines. Expert Opin Drug Saf. 2015 Feb; 14(2):317-24.
Score: 0.430
-
Loh CH, Donohue JF, Ohar JA. Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Mar; 14(3):463-72.
Score: 0.428
-
Ohar JA, Crater GD, Emmett A, Ferro TJ, Morris AN, Raphiou I, Sriram PS, Dransfield MT. Fluticasone propionate/salmeterol 250/50 µg versus salmeterol 50 µg after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014 Sep 24; 15:105.
Score: 0.419
-
Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis. 2013 Apr; 7(2):81-6.
Score: 0.368
-
Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8.
Score: 0.350
-
Ohar J, Fromer L, Donohue JF. Reconsidering sex-based stereotypes of COPD. Prim Care Respir J. 2011 Dec; 20(4):370-8.
Score: 0.345
-
Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010 Jun; 31(3):321-33.
Score: 0.310
-
Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER. Do symptoms predict COPD in smokers? Chest. 2010 Jun; 137(6):1345-53.
Score: 0.307
-
Ohar JA, Hamilton RF, Zheng S, Sadeghnejad A, Sterling DA, Xu J, Meyers DA, Bleecker ER, Holian A. COPD is associated with a macrophage scavenger receptor-1 gene sequence variation. Chest. 2010 May; 137(5):1098-107.
Score: 0.303
-
Donohue JF, Ohar JA. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004; 1(3):152-60.
Score: 0.199
-
Mahler DA, Ohar JA, Ferguson GT, Donohue JF. Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important. Am J Respir Crit Care Med. 2020 11 15; 202(10):1482.
Score: 0.160
-
Macrea M, Oczkowski S, Rochwerg B, Branson RD, Celli B, Coleman JM, Hess DR, Knight SL, Ohar JA, Orr JE, Piper AJ, Punjabi NM, Rahangdale S, Wijkstra PJ, Yim-Yeh S, Drummond MB, Owens RL. Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 08 15; 202(4):e74-e87.
Score: 0.158
-
Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers. Chest. 2020 10; 158(4):1413-1419.
Score: 0.154
-
Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:585-595.
Score: 0.143
-
Braman SS, Carlin BW, Hanania NA, Mahler DA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Dhand R. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848.
Score: 0.135
-
Dhand R, Mahler DA, Carlin BW, Hanania NA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Braman SS. Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839.
Score: 0.133
-
Ghosh S, Ohar JA, Drummond MB. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2017 Dec; 30(6):381-387.
Score: 0.129
-
Kumbhare S, Pleasants R, Ohar JA, Strange C. Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016 06; 13(6):803-10.
Score: 0.118
-
Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C. Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. J Asthma. 2016 09; 53(7):720-31.
Score: 0.117
-
Pleasants RA, Heidari K, Wheaton AG, Ohar JA, Strange C, Croft JB, Liao W, Mannino DM, Kraft M. Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. COPD. 2015; 12(6):680-9.
Score: 0.112
-
Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C. Smoking duration, respiratory symptoms, and COPD in adults aged =45 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2015; 10:1409-16.
Score: 0.111
-
Liu Y, Pleasants RA, Croft JB, Lugogo N, Ohar J, Heidari K, Strange C, Wheaton AG, Mannino DM, Kraft M. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir Med. 2015 Jul; 109(7):851-9.
Score: 0.110
-
Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD. 2014 Jun; 11(3):256-66.
Score: 0.098
-
Sadeghnejad A, Ohar JA, Zheng SL, Sterling DA, Hawkins GA, Meyers DA, Bleecker ER. Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res. 2009 Mar 12; 10:21.
Score: 0.071
-
Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
Score: 0.068